Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Novo and Lilly cut prices of weight-loss drugs in China - 2How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- 3Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
- 4Passenger Missing After Going Overboard Disney Cruise Ship
- 5Norovirus is spreading earlier again this year, wastewater data shows
- Ancient fire discovery marks significant milestone in human history
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Fundamental Venture The board Apparatuses for Remote Groups
- Journey Travel Objections for Your Next Experience
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- How Mars 'punches above its weight' to influence Earth's climate
- \Step by step instructions to Pick the Best Material Organization for Your Home\
